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Summary Exogenous purines () 10-SM) can modulate the cytotoxicity of methotrexate (MTX) in cultured
cells, protecting cells at low MTX concentrations (S 8 x 10-8M) and markedly potentiating its effect at higher
concentrations. The ability of hypoxanthine (HX) to modulate the effects of two antifolates-ICI 198583 (an
inhibitor of thymidylate synthetase) and piritrexim (PTX, a lipophilic inhibitor of DHFR)-was investigated
using cultured mouse leukaemic cells, L1210. HX (10-4M) was found to potentiate only the cytotoxicity of
DHFR inhibitors (MTS and PTX), increasing cell kill by 20-70 fold to the level achieved by an equivalent
concentration (10-5M) of ICI 198583 alone. Agarose gel electrophoresis of DNA extracted from cells exposed
to antifolates for 24 h demonstrated that the chromatin was cleaved into multimers of 200 base pairs. This
pattern of DNA cleavage indicates cell death via apoptosis. The degree of DNA fragmentation was found to
be closely linked to cytotoxicity. DNA fragmentation increased from 50% in cells treated with 10-5M MTX or
PTX to 70% when HX was added with the drugs, a level achieved by 10-5M ICI 198583 alone. HX
potentiation of cytotoxicity was correlated with a substantial increase in dATP in conjunction with low dTTP
pools. The specific potentiation of DHFR inhibitors by HX may be due to their inhibition of purine synthesis
with a concurrent rise in PRPP levels. Addition of HX with MTX substantially raised intracellular purine
levels via the salvage pathway as indicated by ribonucleotide pool measurements. ICI 198583, on the other
hand, stimulated de novo purine synthesis with or without added HX. Treatment with MTX plus HX or ICI
198583 (with or without HX) caused a reduction of dTTP pools to 8% of untreated control and excess dATP
accumulation. The subsequent elevation (to 300% of control) of the dATP pool may provide a signal for
endonucleolytic fragmentation of DNA and subsequent cell death.
Biochemical studies have traditionally focused on the role of
methotrexate (MTX) as an inhibitor of the dihydrofolate
reductase (DHFR) enzyme, causing a depletion of the
reduced folate pool and subsequent inhibition of thymidylate
synthesis (Cadman, 1983). However, the polyglutamylated
forms of MTX have also been found to be potent inhibitors
of some other folate-dependent enzymes involved in purine
synthesis and folate conversions (Allegra et al., 1984). The
sites of action of MTX and its polyglutamylate derivatives on
purine and thymidylate synthesis are illustrated in Figure 1.
Exogenous purines only rescued cultured cells from the
cytotoxic effects of low concentrations (below 8 x 10-8M) of
MTX. At higher MTX concentrations, exogenous purines
markedly potentiated the cytotoxicity of MTX (Taylor et al.,
1982). The purines were thought to either increase the
cytotoxicity of MTX (Borsa & Whitemore, 1969; Fairchild et
al., 1988) or else become toxic in themselves (Taylor et al.,
1982; Yoshioka et al., 1987a). Recent studies have reported
that MTX treated NIH/3T3 cells accumulated single-
stranded and double-stranded DNA breaks preceding cell
death and that the DNA damage was prevented by the
inhibition of protein synthesis by cycloheximide (Lorico et
al., 1988). DNA extracted from MTX treated HL-60 cells
and electrophoresed on an agarose gel has been reported to
be fragmented into multimers of approximately 200 base
pairs (bp) (Kaufmann, 1989). This is a characteristic
biochemical marker for a mode of cell death known as
apoptosis or programmed cell death (Wyllie et al., 1984).
In this study, we compared the effects of HX on the
cytotoxicity of two non-classical antifolates with MTX in
murine leukaemic L1210 cells. Hx (10-4 M) was used because
it was reported to be the highest non-toxic concentration
which elicited the maximum potentiation of MTX cytotox-
icity in L1210 cells (Taylor et al., 1982). Piritrexim (PTX) is a
small lipid soluble diaminopyrido-pyrimidine inhibitor of
DHFR (Figure 1) which is not polyglutamylated in cells
(Duch et al., 1982). ICI 198583 (2-desamino-2-methyl-10-
propagyl-5,8-dideazafolic acid) is a quinazoline-based
inhibitor of thymidylate synthetase (Figure 1) and is the
2-desamino, 7-methyl derivative of the prototype drug, N'l-
propagyl-5,8-dideazafolate CB3717. This modification in-
creased the solubility of the drug and the cytotoxicity by
40-fold (IC50 = 0.09 mM) (Hughes et al., 1988).
Materials and methods
Chemicals
Methotrexate was obtained as a solution (25 mgml') from
David Bull laboratories (Lexia Place, Victoria, Australia).
Piritrexim was obtained from Burroughs Wellcome Co
(Research Triangle Park, NC, USA) and ICI 198583 was a
gift from Dr A. Jackman (Institute of Cancer Research,
Surrey, UK). Piritrexim and ICI 198583 were made up as
mm stock solutions. ICI 198583 was dissolved in 0.15 M
NaHCO3 and PTX in water. Hypoxanthine was made up
freshly as a 10 mM solution and 1O M NaOH solution was
added dropwise until the drug was dissolved. 3H-labelled
deoxynucleosides were purchased from Radiochemical Centre
(Amersham, Buckinghamshire, UK). Unlabelled deoxynucle-
otides were purchased from Sigman Chemical Co. (St Louis,
MO, USA) and PL Biochemicals Inc. (Milwauke, WI, USA).
DNA polymerase (Klenow fragment) was obtained from
Pharmacia, USA. The poly deoxyadenylate-deoxythymidylate
template was purchased from Miles laboratories (Elkhart,
IN, USA).
Cell culture
Mouse leukaemia L1210 cells were grown in suspension cul-
ture in Roswell Park Memorial Institute Medium (RPMI)
1640 supplemented with 10% non-dialysed fetal calf serum
(FCS), L-glutamine and gentamicin (32 mg ml-). The doubl-
ing time of the cells was approximately 11-12h. In all
experiments, cells were set up at 5 x 104 cells ml-' and
allowed to grow undisturbed for 24 h before addition of
drugs. All treatments were carried out with exponentially
growing cell cultures. Cell counts were made by phase-
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Figure 1 Pathway of purine and thymidylate synthesis and sites
of action of antifolates. Methotrexate (MTX) inhibits the dihyd-
rofolate reductase (DHFR) enzyme, but its polyglutamylated
derivatives (MTX(Glu)n) can also directly inhibit de novo purine
synthesis and thymidylate synthetase. Piritrexim (PTX) is a
specific inhibitor of DHFR while ICI 198583 is a potent inhibitor
of thymidylate synthetase. Inhibition of purine synthesis leads to
an elevation ofphosphoribosylpyrophosphate (PRPP) level which
enhances hypoxanthine (HX) conversion to inosine monophos-
phate (IMP). N-glycinamide ribonucleotide (GAR); 5-aminoimid-
azole-4-carboxamide ribonucleotide (AICAR); N-succino-AICAR
(SAICAR); dihydrofolate (FH2); tetrahydrofolate (FH4); 5,10-
methenyl-tetrahydrofolate (CHFH4); I0-formyltetrahydrofolate
(CHOFH4); 5,10-methylenetetrahydrofolate (CH2FH4).
contrast microscopy which was used to discriminate between
live (phase-positive) and dead (phase-negative) cells.
Microtitration cloning assay
Cells were washed once and resuspended in drug-free
medium. A viable cell count was made and the culture
diluted to the required cell number. The cells were distributed
in 200 ml of drug-free medium per well, into 96 well round-
bottom plates (Crown Corning, Liverpool, NSW) using a
Titertek multichannel pipette (Flow Laboratories). Cloning
efficiency was determined by plating doubling dilutions of
viable cells ranging from 5 to 0.625 cells well, with 48 wells
for each dilution. If drug treatment resulted in a high number
of negative wells, the cells were plated at 10 x higher con-
centration. The plates were incubated in a humidified 10%
C02, 5% 02 atmosphere and the wells were inspected for
positive colonies after 14 days. The cloning efficiency of the
cells was calculated from the proportion of negative wells
using Poisson statistics and x2 minimisation (Taswell, 1981).
Cloning results were expressed as colony forming units
(c.f.u.)ml1' which were calculated from percentage cloning
efficiency times viable cell concentration ofcultures at time of
cloning. The cloning efficiency of the control culture of
L1210 cells was 100%.
DNA extraction
A total of 1 x 107 cells were washed once in PBS and lysed in
a 0.05 M Tris.Cl buffer (pH 8), containing 10 mM EDTA,
0.1 M NaCl, 0.5% SDS and 200mgml-I proteinase K (Sigma
Chemical Co.). The lysate was incubated at 50°C for 3 h
before being extracted with phenol (twice), chloroform/
isoamyl alcohol (24:1) (twice) and ether (twice). The sample
was then treated with 100 mgml' RNAse A (Sigma
Chemical Co.) for 1 h at 37°C and then with 200 mgml1
proteinase K for 1 h at 37°C. The sample was extracted again
with phenol and chloroform and the DNA concentrated by
Centricon centrifugation (Amicon, Danvers, MA, USA) to
prevent loss of fragmented DNA. An amount of 1Omg of
DNA from each sample was analysed by electrophoresis on a
1% agarose gel containing ethidium bromide (0.3 figml-')
using 1 x TAE buffer (0.04 M Tris-acetate; 0.001 M EDTA).
DNAfragmentation assay
The degree of DNA fragmentation was quantified using
centrifugation to separate intact chromatin from fragmented
DNA (Sellins & Cohen, 1987). A total of 3 x 106 cells were
washed once in PBS (Dulbecco's phospate buffered saline)
(Cytosystems, Castle Hill, NSW) and lysed with 0.4 ml
hypotonic lysing buffer (pH 7.5) containing 10 mM Tris.Cl,
1 mM EDTA and 0.2% Triton X-100. The lysate was
incubated on ice for 15 min and then centrifuged at
13000g for 10min. Both the supernatant and the pellet was
precipitated separately in 12.5% trichloroacetic acid (TCA)
at 4°C overnight. The precipitate was pelleted at 110OOg for
4min.
The DNA in the precipitate was hydrolysed by heating to
90°C for 10 min in 80 ml 5% TCA and quantified using a
modification of the diphenylamine method (Sellins & Cohen,
1987). The degree of DNA fragmentation refers to the
percentage of DNA in the 13000g supernatant divided by
the total DNA from the pellet and supernatant.
Ribonucleotidepool assay
Approximately 1 x 108 cells were washed twice in cold PBS
and extracted with cold 0.6 M perchloric acid (Kemp et al.,
1986). The neutralised extracts were subjected to HPLC
analysis (Sant et al., 1989) to determine the relative quantity
of purine and pyrimidine nucleotides. The eluted metabolites
were monitored by an LK2140 rapid spectral detector con-
nected to an IBM XT microcomputor (Sant et al., 1989;
Lyons & Christopherson, 1990). The area under each peak
was calculated using the Nelson Analytical 3000 series
chromatography data system (Version 5.0). The results were
expressed as percentage area of the untreated control
(derived from the mean of the 0, 6 and 12 h samples).
Deoxyribonucleoside triphosphate pool assay
A total of 5 x 106 viable cells were washed once in cold PBS
(with 2 mM EDTA) and extracted with ice cold 60% ethanol.
The extract was lyophilised and resuspended in 500 ml of
10mM Tris buffer (pH 7.85). The sample was then centri-
fuged at 11000g for 15 min at 4°C and the supernatants
stored at - 20°C. The deoxyribonucleotides were measured
by a modification of the DNA polymerase assay (Mann &
Fox, 1986). The concentrations of the deoxyribonucleoside
triphosphates were determined from calibration curves of
picomole amounts of pure standards.
Results
A microtitration cloning assay was used to determine the
effects of HX on MTX and the results shown in Figure 2a
are similar to those using a soft agar cloning assay (Taylor et
al., 1982). Using the same microtitration assay two other
antifolates, PTX and ICI 198583 were also tested. The effects
of 24 h exposure to ICI 198583 (the inhibitor of thymidylate
synthetase) in the presence or absence of exogenous HX is
shown in Figure 2b. For the three different concentrations of
the drug used (10-7, 10-6 and 10-5M), the addition of 10-4M
HX had no significant effect on the cytotoxicity of ICI
198583. On the other hand, when PTX (an inhibitor of
DHFR) was used, there was a marked potentiation ofHYPOXANTHINE POTENTIATION OF ANTIFOLATE ACTION 505
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Figure 2 Modulation of antifolate cytotoxicity by HX in L1210 cells. (S) Drug alone; (0) drug plus 10-4M HX. Cytotoxicity
was determined using a microtitration assay (as described in methods). Drug exposure time was 24 h; s.e.m. derived from plating
four serial dilutions (48 wells/dilution) or each drug concentration point.
cytotoxicity at concentrations at or greater than 10-7M.
There was no protection at a lower drug concentration
(10-8M) as shown in Figure 2c.
Electrophoretic analysis of DNA extracted from untreated
and drug-treated cells is shown in Figure 3. The DNA from
the untreated control cells was unfragmented high molecular
weight DNA (Figure 3, lane 2). The addition of 10-4M HX
alone did not result in fragmented DNA (Figure 3, lane 3),
but the addition of 10-'M MTX, PTX or ICI 198583 for
24 h resulted in DNA which was extensively cleaved into the
distinctive multimers of approximately 200 bp (Figure 3, lane
4, 6 and 8 respectively). The addition of 10-4M HX did not
alter the appearance of the bands (Figure 3, lane 5, 7 and 9).
The degree of DNA fragmentation was determined by
separating the cleaved DNA from the intact chromatin by
centrifugation and measuring the amount of DNA present in
the supernatant and pellet using the diphenylamine method
(Sellins & Cohen, 1987). The degree of DNA fragmentation
refers to the ratio of DNA in the supernatant to the total
DNA in the supernatant and pellet. The degree of DNA
fragmentation in the untreated control and in cells exposed
to the antifolates for 24 h is shown in Figure 4. The back-
ground fragmentation in the untreated control was approx-
imately 5%. The addition of 10-4M HX alone did not
significantly (P> 0.5; Student's t-test) increase the degree of
fragmentation. However, when 10-5M MTX or PTX was
added together with HX, there was a 20% (P<0.01) inc-
rease in fragmentation. This was associated with the poten-
tiation of the cytotoxicity of MTX and PTX by HX (Figure
2a and c). In contrast, the addition of HX with 10-5M ICI
198583 made little difference (3%) to the degree of fragmen-
tation compared with ICI 198583 alone. This finding is in
agreement with the lack of potentiation of ICI 198583
cytotoxicity by HX (Figure 2b).
To explore the possible biochemical mechanisms underly-
ing purine potentiation, the perturbations of the ribo-
nucleotide and deoxyribonucleoside triphosphate pools were
measured in cells treated with 10-5M MTX or ICI 198583 in
the absence or presence of 10-4M HX.
Since MTX depletes folate pools and its polyglutamylated
derivatives inhibit specific enzymes involved in the purine
synthesis pathway, the pools of the four ribonucleotides
(ATP, GTP, CTP and UTP) as well as two purine inter-
mediates (SAICAR and IMP) were measured over a 24h
period following the addition of the drugs. As shown in
Figure 5a, 10-5M MTX tended to reduce particularly after
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Figure 3 Agarose gel electrophoresis of DNA from L1210 cells
exposed to antifolates. A 10- M concentration of the antifolates
was used. + and - indicate the addition or absence of 10-4M
HX. Drug exposure time was 24 h. Approximately 10 fig ofDNA
from each sample was analysed on a 1% agarose gel. DNA size
markers (lane 1) were derived from a Pst 1 restriction enzyme
digestion of A phage DNA (Sigma).
12 h the purine precursor pools and ATP and GTP levels
(Figure Sb). This was accompanied by an increase in the
pyrimidine pools (UTP and CTP) after 12 h as shown in
Figure Sc. When 10-4M HX was added with MTX, there was
an increase in all four ribonucleotide pools (1.5-2-fold) as
well as a sharp rise (three-fold) in the IMP pool when
compared with the untreated control. In cells treated with
10-5M ICI 198583, there was a rise in all the ribonucleotide
and precursor pools (Figure Sd, e and f). The addition of HX
with ICI 198583 made little difference in the ribonucleotide
pools, but there was an increase in the IMP pools.
Prevous reports have shown that purine potentiation of
MTX cytotoxicity was closely associated with a marked incr-
ease (three-fold) in intracellular dATP pool (Taylor et al.,
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1982). Our experiments using the same DNA polymerase
assay to determine the deoxyribonucleoside triphosphate pool
perturbations have shown a similar increase in dATP pool
after 12 h as shown in Figure 6a. However, in cells treated
with 10-SM ICI 198583 alone, there was also a substantial
increase (three-fold) in the dATP pool after 12 h drug
exposure as shown in Figure 6b. The addition of 10-4M Hx
with ICI 198583 did not increase the dATP pool further.
Both MTX with HX and ICI 198583 with or without
exogenous HX, depressed the dTTP pool levels to a similar
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Figure 4 Degree of DNA fragmentation in L1210 cells treated
with antifolates in the presence ( 1 ) or absence (0) of 10-4M
HX. Drug exposure time was 24 h. A 10-5M concentration of
each antifolate was used. Means ± s.d. were derived from a total
of nine replicates from three separate experiments.
extent as shown in Figure 6a and b. HX by itself caused
minor perturbations in dATP (111 ± 1.47% (mean ± s.d.)
and dTTP (79 ± 11%) after 12 h exposure.
Discussion
The cytotoxicity of MTX has been shown to be modulated
by the presence of exogenous purines (Taylor et al., 1982).
This study compares the ability of a preformed purine
(hypoxanthine) to modulate the cytotoxicity of two other
antifolates: PTX, an inhibitor of DHFR which is not poly-
glutamylated in cells (Duch et al., 1982) and ICI 198583, a
potent inhibitor of thymidylate synthetase (Hughes et al.,
1988; Jackman et al., 1988; 1990).
Using a microtitration cloning assay, 10-5M ICI 198583
was found to be more toxic (reducing the number of c.f.u.
ml-' to 0.02% of the untreated control) than 10-SM MTX
(1.1%) or 10-5M PTX (0.6%). The addition of 100mM HX
potentiated the cytotoxicity of the two inhibitors of DHFR
(MTX and PTX), increasing their cytotoxicity to the same
level as ICI 198583 alone. This potentiation of the cytotox-
icity of the DHFR inhibitors by HX was also observed in
cells treated with metoprine, a lipophilic inhibitor of DHFR
(data not shown). As with ICI 198583, HX did not affect the
cytotoxicity of another thymidylate synthetase inhibitor, 5-
fluorodeoxyuridine (FUdR) (data not shown).
Two hypotheses may explain the purine potentiation of the
DHFR inhibitors. Firstly, Fairchild et al. (1988), after perf-
orming tritiated uridine uptake and cell cycle studies, conc-
luded that the potentiation of MTX cytotoxicity in L1210
cells by HX was due to the restoration of normal RNA
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Figure 5 Changes in intracellular levels of purine precursor and ribonucleotide pools with time in L1210 cells treated with either
10-5M MTX (a, b and c) or 10-5M ICI 198583 (d, e and f) in the presence (open symbols) or absence (shaded symbols) of 10-4M
HX. (0, *) IMP; (A, A) SAICAR; (0, 0) ATP; (O, *) GTP; (V, V) UTP; (*, *) CTP. Points obtained from a mean of
values from two separate experiments.
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Figure 6 Changes in intracellular levels of dATP and dTTP with
time in L1210 cells treated with either (a) 10-5M MTX or (b)
10-5M ICI 198583. (0, 0) dATP; (A, A) dTTP. (0, A) drug
alone; (0, A) drug plus 10-4M HX. Means ± s.d. were obtained
from a total of four replicate from two separate experiments. All
results expressed as a percentage of the zero hour untreated
control. Control levels (pmol/106 cells) of dATP and dTTP in
were 10 ± 2 (mean ± s.d.) and 19 ± 4 respectively.
synthesis, which allowed cells to progress onto the more
lethal S phase. That is, HX increases the number of cells
susceptible to the cytotoxic mechanisms of MTX. This may
involve dUTP incorporation into DNA during genomic repl-
ication and subsequent single-stranded breaks in the DNA
(Goulian et al., 1980). However, measurements of RNA and
DNA contents of CCRF-CEM (F2) cells treated with 0.1 mM
MTX have shown that while HX allowed continued RNA
synthesis, the block in cell cycle progression was only over-
come by the addition of thymidine and HX (Taylor & Tat-
tersall, 1981). This inability of HX to alleviate the block was
also demonstrated in other cell lines (Sen et al., 1990).
The other hypothesis is that the purines may become toxic
themselves. This is based on a study ofcytotoxicity involving
a series of preformed purines in conjunction with MTX.
There was a strong relationship between the extent of purine
potentiation of MTX and their effects on the dATP pools
(Taylor et al., 1982). The link between cytotoxicity and an
increase in dATP pool may be due to several mechanisms. A
rise in dATP pool has been shown to inhibit DNA repair of
single-stranded DNA breaks in resting lymphocytes either by
blocking ribonucleotide reductase (which inhibits de novo
dNTP synthesis) or DNA ligation (Meuth, 1989; Seto et al.,
1986). Moreover, dNTP pool balance is essential for fidelity
in DNA synthesis in dividing cells (Yoshioka et al., 1987b).
Inhibition of either DNA repair or synthesis is sufficient to
cause cell death (Yoshioka et al., 1987a).
The observed differences in dATP pool perturbations
(Figure 6) between MTX, a DHFR inhibitor and ICI 198583,
a thymidylate synthetase inhibitor, may be explained by the
following model. The DHFR inhibitors strongly inhibit de
novo purine synthesis either by lowering the reduced folate
cofactor pools or by direct inhibition of the enzymes involved
in purine synthesis (Figure 1). This results in a rise in phos-
phoribosylprophosphate (PRPP) levels (Cadman, 1979) and
exogenous HX or other purines can be quickly metabolised
to raise the purine ribonucleotide (Figure Sb) levels. In cells
treated with MTX and HX, the synthesis of dTTP was
inhibited (Figure 6a). During S phase, excess dATP would
accumulate due to lack of complementary dTTP nucleotides,
resulting in an elevation of the dATP pool (Figure 6a). On
the other hand ICI 198583 stimulates de novo synthesis
(Figure Se), possibly by inhibiting thymidylate synthetase and
sparing the reduced folates for purine synthesis. This may be
sufficient to cause the three-fold increase in dATP pools, with
or without added HX. This mechanism would explain the
observations of an experiment which involved the use of
synchronised FM3A cells treated with FUdR. The drug
resulted in an elevation of the dATP pool and cell death only
if it was added during S phase. When the drug was added
after S phase, when DNA synthesis was completed, the
dATP pool remained unaffected until the cells cycled to the
next S phase where the dATP pool was elevated by 240%
and followed by cell death (Yoshioka et al.,1987b).
A previous report has shown that MTX treated HL-60
cells die via a regulated process known as apoptosis (Kauf-
mann, 1989). Apoptosis also requires protein synthesis and is
characterised by the activation of an endonuclease which
cleaves DNA at the internucleosomal linker regions produc-
ing fragments of approximately 200 bp multimers (Wyllie et
al., 1984). A study using a rat prostatic cancer cell line
showed that FUdR clearly resulted in the cleavage of the
DNA into 200 bp multimers (Kyprianou & Issacs, 1989).
DNA extracted from L1210 cells treated with 10-5M MTX,
PTX or ICI 198583 for 24 h was also fragmented into the
characteristic multimers of 200 bp, indicating that antifolate
treated cells die via apoptosis. The degree of DNA fragmen-
tation was increased significantly by 20% when HX was
added with MTX or PTX, but only by 3% with ICI 198583
treatment. This correlation between DNA fragmentation and
cytotoxicity suggests that the increase in cytotoxicity may
also be via the apoptotic pathway.
We postulate that the addition of HX with MTX allowed
an increase in dATP pools during DNA synthesis. This
elevation in dATP then serves as a strong signal (in the same
manner as ICI 198583) for cells to commit themselves to the
apoptotic pathway. Other studies have already shown that an
inhibitor of de novo purine synthesis-5,10-
dideazatetrahydrofolate (Moran et al., 1985) protected cells
from the effects of a thymidylate synthetase inhibitor, CB
3717 (Gallivan et al., 1988). Further studies on the interac-
tions between these antifolates should clarify whether the
elevation of dATP pools is the main cytotoxic mechanism of
purine potentiation and perhaps of antifolate treatment per
se.
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